EZRA — Reliance Global Group Inc.

Summary of Reliance Global Group Q4 2025 Earnings Call

1. Key Financial Results and Metrics:

• Commission Income: $12.4 million for 2025, down from $14.1 million in 2024, primarily due to strategic divestitures.
• Commission Expense: Increased to $4.6 million from $4.2 million, reflecting higher sales activity.
• Salaries and Wages: Rose to $10.3 million from $7.2 million, mainly due to noncash share-based compensation.
• General and Administrative Expenses: Increased to $4.9 million from $4.2 million, driven by noncash equity awards.
• Net Loss: Improved to $7 million from $9.1 million in 2024.
• Adjusted EBITDA: Loss of $1.6 million, compared to a loss of $0.3 million in 2024.
• Balance Sheet Improvements:
  • Unrestricted cash increased 250% to $1.3 million.
  • Working capital improved by 351% to $1.9 million.
  • Stockholders' equity rose 114% to $6.4 million.

2. Strategic Updates and Business Highlights:

• The company is transitioning towards a technology-driven growth platform, focusing on two pillars: its insurance and InsurTech operations and the EZRA International Group with the Scale51 model.
• RELI Exchange: Generated strong growth, with personal lines premiums up 36% and health insurance policies written up 72% year-over-year.
• Divestitures: Sold non-core subsidiaries (Fortman Insurance Services, Employee Benefits Solutions, U.S. Benefits Alliance) to simplify operations and focus on high-growth opportunities.
• Investments: Initial investments in Enquantum (post-quantum encryption technology) and an agreement to acquire a majority stake in Scentech Medical (AI diagnostic technology).

3. Forward Guidance and Outlook:

• The company is optimistic about the Scale51 strategy, expecting revenue generation from Enquantum potentially within the year.
• The management believes that the combination of stable insurance operations and targeted technology investments will create long-term value for shareholders.

4. Bad News, Challenges, or Points of Concern:

• Declining Commission Income: The decrease in commission income due to divestitures raises concerns about revenue stability.
• Operating Losses: Continued operating losses and negative adjusted EBITDA indicate ongoing financial challenges.
• Market Risks: The transition to technology-driven initiatives may face competitive pressures and execution risks, particularly in emerging sectors like cybersecurity and AI.

5. Notable Q&A Insights:

• Management expressed excitement about the Scale51 strategy, emphasizing a focus on companies close to revenue generation.
• Enquantum is seen as a critical investment, with potential revenue expected soon, highlighting the urgency of developing post-quantum encryption technologies.
• Scentech Medical's technology for early disease detection was discussed as a significant advancement in diagnostics, with the potential for life-saving outcomes.

Overall, while Reliance Global Group made notable progress in restructuring and strategic focus during 2025, challenges remain in revenue generation and profitability as the company pivots towards technology-driven growth.